Abivax Announces $235.8 Million IPO

New York - October 20, 2023 - Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering. Partners Div Gupta, Marc Recht, Ryan Sansom and Denny Won led the Cooley team.

Abivax offered a total of 20,325,500 ordinary shares - consisting of 18,699,460 American depositary shares and 1,626,040 ordinary shares in certain jurisdictions outside the US - priced at $11.60 per share, with a 30-day option for the underwriters to purchase up to 3,048,825 additional ordinary and/or American depositary shares. The listing is now trading on the Nasdaq Global Market under the symbol ABVX.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.